Mechanisms and management of retinopathy of prematurity. - Wikidata - wikimedia - TriplyDB

Mechanisms and management of retinopathy of prematurity.

Mechanisms and management of retinopathy of prematurity.

http://www.wikidata.org/entity/Q38069895

about

D-Penicillamine for preventing retinopathy of prematurity in preterm infants The unfolded protein response in retinal vascular diseases: implications and therapeutic potential beyond protein folding Brain development after neonatal intermittent hyperoxia-hypoxia in the rat studied by longitudinal MRI and immunohistochemistry.Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment.Fatty acid binding protein 4 deficiency protects against oxygen-induced retinopathy in mice PPARα regulates mobilization and homing of endothelial progenitor cells through the HIF-1α/SDF-1 pathway.Involvement of plasmalogens in post-natal retinal vascular development.Adenosine receptors and caffeine in retinopathy of prematurity.Genetic variants associated with severe retinopathy of prematurity in extremely low birth weight infants Metabolomic Analysis of the Effect of Postnatal Hypoxia on the Retina in a Newly Born Piglet Model Pulmonary surfactant protein a is expressed in mouse retina by Müller cells and impacts neovascularization in oxygen-induced retinopathy Stimulating retinal blood vessel protection with hypoxia-inducible factor stabilization: identification of novel small-molecule hydrazones to inhibit hypoxia-inducible factor prolyl hydroxylase (an American Ophthalmological Society thesis).VEGF mRNA and protein concentrations in the developing human eye.Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity Visual impairment due to retinopathy of prematurity (ROP) in New Zealand: a 22-year review.Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis Relationship between mean platelet volume and retinopathy of prematurity.Retinopathy of prematurity: New developments bring concern and hope.A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity.Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity.Insulin, Hyperglycemia, and Severe Retinopathy of Prematurity in Extremely Low-Birth-Weight Infants.Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index.Cytochrome P450 Oxidase 2C Inhibition Adds to ω-3 Long-Chain Polyunsaturated Fatty Acids Protection Against Retinal and Choroidal Neovascularization.Sildenafil attenuates vaso-obliteration and neovascularization in a mouse model of retinopathy of prematurity.Visual outcome and refractive status in first 3 years of age in preterm infants suffered from laser-treated Type 1 retinopathy of prematurity (ROP): a 6-year retrospective review in a tertiary centre in Hong Kong.Inner retinal oxygen metabolism in the 50/10 oxygen-induced retinopathy model.Retinopathy of prematurity in Indonesia: Incidence and risk factors.CCN1/Cyr61-PI3K/AKT signaling promotes retinal neovascularization in oxygen-induced retinopathy ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy Adenosine A1 Receptors Selectively Modulate Oxygen-Induced Retinopathy at the Hyperoxic and Hypoxic Phases by Distinct Cellular Mechanisms.Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity Short hairpin RNA-mediated knockdown of VEGFA in Müller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity.In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen-Induced Retinopathy Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity.ELBW survivors in early adulthood have higher hepatic, pancreatic and subcutaneous fat.Bioelectric impact of pathological angiogenesis on vascular function.Retinal expression of small non-coding RNAs in a murine model of proliferative retinopathy.Advances in diagnosis, clinical care, research, and treatment in retinopathy of prematurity.

P2860

Q24198241-5A048262-D65E-4FB3-9118-8A94B486656B Q26852080-C8B72222-B792-44C5-A0B7-A2E7A7158EE3 Q30720485-3C843B86-6F46-4615-963E-207FF3D5ACFA Q33561241-88994685-8B73-46FA-9BE3-972E911D055F Q33572886-A5719BD4-2FE0-40AE-9B81-D7F3D677B8DD Q33782638-947A4C95-E0C3-4316-B2CE-3E67D24DCB86 Q33807122-50123B0A-35DD-45F6-8A15-0FC45E77240E Q33860622-8CCB02DB-4BCD-45C7-B427-B33A7F3BA222 Q34299394-BFE89E29-1AFD-47CC-9B5F-ED9511A49584 Q34792506-238CADB4-412D-48AC-8BA8-9A20BF4A1B51 Q34912658-0EADB979-1B71-456C-9A3E-0925E16204CC Q35079777-4037BAF3-B334-4BA0-8895-822FF9ED3639 Q35186649-9643B7D1-E0F8-4E53-BC88-6FD77110877A Q35473907-EC4A22D6-AB44-4ADA-AC9E-9CE1298D07B4 Q35531405-D9FF047D-76EE-4CF3-9D99-F5ED5AAA196A Q35553854-8E0623E3-2A68-400C-9259-384AF649F2BC Q35573399-6599B775-EA1D-4CAF-8AA5-3A11204216AA Q35574624-52D372DC-774D-46C1-91F9-2CCCDC557BC3 Q35665701-EEA8C0E6-E473-437B-92F6-027C1ACB8FB5 Q35776253-0CC63D28-9EBB-476A-B778-52591F4CBC01 Q35814629-9061F449-96B4-46D2-89BC-A9CCAB3B4974 Q35984783-4C30578C-5D16-4AC6-9904-50043D76E01F Q36040633-E8482C26-CB15-4D5E-BAB1-1F20B249366F Q36078137-DDD692E0-3EA3-4834-AA02-6F4712AF2A53 Q36103389-FE4597E8-476B-4C63-A5D4-7799298296C9 Q36239999-1501FF71-D120-4830-B06D-865B3B56A4F8 Q36291702-C9CE1C26-B9FE-43CA-A6A9-249CFCA48146 Q36311820-076175EA-C35C-4F55-815E-E0F917D4258E Q36369272-F2BF4D86-2A3F-4099-BF46-C542BC9D9713 Q36374238-6B629EB9-4D12-4FEF-9765-B490CBDB343D Q36379513-322726F5-74C1-4C0F-9CAD-E834FA6A77F0 Q36424969-07B4F6B3-CFD8-4E70-B5F2-5A66480C666F Q36752978-03C9D082-0F86-46D3-B787-2F7543F3AED7 Q37149035-C32DF140-7216-47E8-8ED2-F4DCA8F9ABAD Q37153715-BFB7FF10-294A-4082-8CD4-E95DEF0BA9B3 Q37173066-F28B6892-A1FD-446B-B574-ED65FCA0C5B1 Q37181375-EC78570E-B952-4B66-A23B-426A1CFEACE2 Q37258464-EBE56D47-73A4-49C4-8EC7-5B11363F67E4 Q37274155-48DD87BD-C375-4128-AB09-BD9C11D000C9 Q37370267-A3AA59DF-2B52-4B04-9DA3-D3D10D7806B3

P2860

Mechanisms and management of retinopathy of prematurity.

http://www.wikidata.org/entity/Q38069895

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Mechanisms and management of retinopathy of prematurity.

@en

type

label

Mechanisms and management of retinopathy of prematurity.

@en

prefLabel

Mechanisms and management of retinopathy of prematurity.

@en

P1433

Q38069895-34AB9A08-321D-4397-91F2-D82774F5559D

P1476

Q38069895-FB4F3BFB-823E-4E25-B3E6-31386839FE8D

P2093

Q38069895-2D286325-112F-45C6-9F22-131F75744165

Q38069895-A6F340D6-026E-4E50-A896-AA7F452453E7

P2860

Q38069895-011F2697-C083-43F4-B638-F8AA01B04208

Q38069895-15866CEB-02F4-4281-9B01-C24CAE468DFE

Q38069895-165980C0-11C3-41CA-8F64-CA82A76B417F

Q38069895-1BB640B3-389A-4103-B728-9913972A37AC

Q38069895-1F5AA5E1-C6F1-4FF8-BF63-EE4A7C27966E

Q38069895-2AA42EB1-2096-437B-92C6-7A3057623658

Q38069895-2CA2B5BA-9DE1-43AB-A159-7939FEBF48E7

Q38069895-2D2A14EA-644B-4653-AF67-BEC0920FCF7D

Q38069895-2D6B7759-B8EA-4312-AE3C-9941492BDD13

Q38069895-32317E56-3A21-46C1-BCEB-931DBA8804F1

P304

Q38069895-A9D6BA3A-5BE4-494E-A0E1-097A70F330F6

P31

Q38069895-755F493F-820B-4AB9-9C35-8773E420E690

P356

Q38069895-B3EFABBB-4CC9-4765-8E79-2B82C5203BC8

P407

Q38069895-60E7D957-8B5F-4E3E-AAD7-AC54FA98FB71

P433

Q38069895-3157FB74-5FDA-4490-B087-DAC62AF1F526

P478

Q38069895-0A43BCDB-80C8-4D9B-AE2A-A975A7106688

P577

Q38069895-B7EC47FC-7B98-4B7E-8101-C1929BBFC1E6

P698

Q38069895-62D0D7EC-0BAE-4749-BC06-11390132DF34

P932

Q38069895-6A7AF3A6-6755-45CE-A8B3-8E742A6B3AB2

P356

P1433

The New England Journal of Medicine

P1476

Mechanisms and management of retinopathy of prematurity.

@en

P2093

John S Penn

http://www.w3.org/2001/XMLSchema#string

M Elizabeth Hartnett

http://www.w3.org/2001/XMLSchema#string

P2860

Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates

Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants

Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity

HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Target ranges of oxygen saturation in extremely preterm infants.

Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation

Ghrelin modulates physiologic and pathologic retinal angiogenesis through GHSR-1a

Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice.

Screening examination of premature infants for retinopathy of prematurity.

P304

2515-2526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMRA1208129

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23268666

http://www.w3.org/2001/XMLSchema#string

P932

3695731

http://www.w3.org/2001/XMLSchema#string